Abstract: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.

Abstract: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.

Abstract: Peptides which bind a cellular (surface or intracellular) receptor, such as a nuclear receptor, may be identified by screening a combinatorial peptide library presented in the form of cells each of which coexpress one member peptide and the receptor, together with a signal producing system for reporting binding. A “two-hybrid” assay is of particular interest. The screen may be carried out in the presence of a ligand, in particular, an exogenous ligand. If this screening is carried out for a plurality of different receptor conformations, then this library screening will also serve to identify conformation-specific peptides for the receptor, which may then be used in a panel for “fingerprinting” query compounds as to their ability to interact with the receptor in the presence of each of the panel peptides. These fingerprints may be compared to those of reference compounds with known biological activities mediated by that receptor.

Abstract: Peptides which bind a cellular (surface or intracellular) receptor, such as a nuclear receptor, may be identified by screening a combinatorial peptide library presented in the form of cells each of which coexpress one member peptide and the receptor, together with a signal producing system for reporting binding. A “two-hybrid” assay is of particular interest. The screen may be carried out in the presence of a ligand, in particular, an exogenous ligand. If this screening is carried out for a plurality of different receptor conformations, then this library screening will also serve to identify conformation-specific peptides for the receptor, which may then be used in a panel for “fingerprinting” query compounds as to their ability to interact with the receptor in the presence of each of the panel peptides. These fingerprints may be compared to those of reference compounds with known biological activities mediated by that receptor.

Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

Abstract: A nucleic acid comprising a base sequence which codes for a CEA peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or infected with such cloning vehicles, polypeptides expressed by such cells, antibody preparations specific for such polypeptides, immunoassays for detecting CEA using such antibody preparations and nucleic acid hybridization methods for detecting a CEA nucleic acid sequence using a nucleic acid probe comprising the above described nucleic acid.

Abstract: A method for aiding in the diagnosis of, and monitoring the progression of, breast cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g. serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of breast cancer in the patient. The progression of breast cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.

Abstract: A nucleic acid encoding a carcinoembryonic antigen (CEA) that cross-reacts with human CEA is described. In addition, vectors and host cells containing such nucleic acids are disclosed.

Abstract: Nucleic acid sequences are disclosed that encode carcinoembryonic antigens (CEAs) as are replicable recombinant cloning vehicles containing DNA that encodes CEA proteins.

Abstract: A nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

Abstract: This invention relates to a nucleic acid comprising a base sequence which codes for a CEA family member peptide sequence or nucleic acids having a base sequence hybridizable therewith, replicable recombinant cloning vehicles having an insert comprising such nucleic acid, cells transfected, infected or injected with such cloning vehicles, polypeptides expressed by such cells, synthetic peptides derived from the coding sequence of CEA family member nucleic acids, antibody preparations specific for such polypeptides, immunoassays for detecting CEA family members using such antibody preparations and nucleic acid hybridization methods for detecting CEA family member nucleic acid sequences using a nucleic acid probe comprising the above described nucleic acid.

Abstract: A ski attachment for protecting the upper surface of a rear portion of a ski is formed as a rigid body of hard impact resistant material having a base securable to the upper surface of a rear surface of a ski. The body is generally triangular in side view with a substantially flat rear face extending upwardly and forwardly from a rear base edge at an angle in the range of from about 35.degree. to about 50.degree. to the base to a vertical height above the base in the range of from about 0.375 to about 0.875 inches.

Abstract: A process for production of a single strand of a nucleic acid comprising covalently linking to a solid substrate a polynucleotide complementary to the desired strand, hybridizing said polynucleotide with an oligonucleotide, extending the oligonucleotide in direction away from said substrate, denaturing the hybridized polynucleotide and extended oligonucleotide, thereby to free the extended oligonucleotide from the solid substrate, and separating the extended oligonucleotide. The product can be used for making analytical probes.